INJ Rally Fueled by ETF Hopes and Institutional Plans

| odaily.news
INJ surged more than 23% on 16 October to about $9.16, extending its gains to roughly 70% over the past month. The rally has been supported by institutional and regulatory developments around Injective. Three spot or staking ETF applications have been filed by 21Shares, Canary Capital and REX-Osprey, while Pentiv, formerly Pineapple Financial, reportedly plans to bring a mortgage portfolio worth up to $10 billion onto the network. Injective CEO Eric Chen also reportedly met US officials at the White House, SEC and CFTC. The IIP-709 governance proposal to set fixed fees for exchange-module orders and cancellations was nearing the end of its vote. The change could appeal to high-volume traders, but its implementation remains a development to watch. The article cautions that INJ’s rally may reflect market positioning and a strong narrative more than improving fundamentals. Its high reported revenue-to-FDV ratio is partly due to INJ’s sharply reduced valuation, with cited estimates putting protocol revenue at about $6 million over the past year. ETF applications are not approvals, and Pentiv’s RWA plan is not yet completed on-chain adoption. Supply figures also remain a point of uncertainty: Mintscan reportedly showed about 123 million INJ, differing from widely cited supply estimates, while staking-related issuance could offset token burns. Traders may monitor open interest, funding rates, large-holder activity and the IIP-709 vote. INJ could remain volatile if leveraged positions unwind or the institutional and RWA catalysts fail to translate into sustained demand.
Bullish
The news is bullish for INJ in the near term because the reported ETF applications, US official meetings, proposed fixed exchange fees and Pentiv’s planned mortgage-portfolio migration have strengthened investor attention and coincided with a sharp price rise. The IIP-709 proposal could also support interest from high-volume traders if approved and implemented. However, the catalysts are not guaranteed to produce lasting demand: ETF filings are not approvals, and the RWA plan has not yet demonstrated completed on-chain activity. The article also questions the strength of Injective’s revenue relative to its valuation and flags uncertainty over token supply and staking-related issuance. Elevated open interest or funding rates could signal crowded leveraged positioning, increasing the risk of a rapid pullback. Longer term, sustained gains would depend on measurable adoption, successful execution of the governance changes and durable demand for INJ; without those, the rally may prove primarily narrative-driven.